SEHK:6990Biotechs
Sichuan Kelun‑Biotech (SEHK:6990) Losses Narrow In 1H 2025 Challenging Bearish Narratives
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has reported FY 2025 first half revenue of C¥950.4 million with a basic EPS loss of C¥0.64, while trailing twelve month revenue stands at C¥2.1 billion and basic EPS over that period is a loss of C¥3.20. The company has seen revenue move from C¥1.38 billion in 1H 2024 to C¥550.3 million in 2H 2024 and C¥950.4 million in 1H 2025, with EPS shifting from a profit of C¥1.41 in 1H 2024 to losses of C¥2.59 in 2H 2024 and C¥0.64 in 1H 2025...